Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5263]

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating...

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Talazoparib plus enzalutamide improves radiographic progression-free survival...

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical...

Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman...

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses ( Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke )

Aspirin in stage III colorectal cancer shows no significant DFS benefit but...

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel...

ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )

Amivantamab in HPV-unrelated mHNSCC gives high response rates after...

Dr Barbara Burtness - Yale Cancer Center, New Haven, USA

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo ( Dr Barbara Burtness - Yale Cancer Center, New Haven, USA )

Gene expression test guided therapy in ER+/HER2- early breast cancer allows...

Dr Robert Stein - University College London, London, UK

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )

MCED blood test trial fails primary end point, but screening cut number of...

Dr Peter Sasieni - Queen Mary University of London, London, UK

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV ( Dr Peter Sasieni - Queen Mary University of London, London, UK )

Fedratinib improves spleen and symptom responses with promising survival...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

177Lu-rosopatamab plus standard of care shows manageable safety and favourable...

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )

More from ecancer